Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

How to optimize HCV therapy in genotype 1 patients: management of side-effects.

Liver international : official journal of the International Association for the Study of the Liver - 1 Feb 2013

Chopra Angeli, Klein Patricia L, Drinnan Thia, Lee Samuel S

Abstract excerpt

Antiviral therapy for chronic hepatitis C has dramatically changed with the advent of triple therapy incorporating direct-acting antivirals (DAAs) such as the protease inhibitors (PI) boceprevir and telaprevir. Such triple-therapy is associated with a new spectrum of side-effects which can hamper quality of life. These may lead to dosage reduction and sometimes discontinuation of therapy. This review presents...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Therapy, Combination
Share to Interferon-alpha

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon alpha-2

Share to Liver Cirrhosis

Share to Patient Selection

Share to Polyethylene Glycols

Share to Ribavirin

Share to Serine Proteinase Inhibitors

Source

Identifiers

PMID: 23286843
DOI: 10.1111/liv.12080

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

How to optimize HCV therapy in genotype 1 patients: management of side-effects.PMID 23286843Read ↗

Safety aspects of protease inhibitors for chronic hepatitis C: adverse events and drug-to-drug interactions.Semantic proximity Read ↗

Hepatitis C therapy update.Semantic proximity Read ↗

Ideal oral combinations to eradicate HCV: The role of ribavirin.Semantic proximity Read ↗

Combination therapy with interferon-alpha and ribavirin for hepatitis C: practical treatment issues.Semantic proximity Read ↗

Management and outcomes of side effects with focus on anaemia in patients with hepatitis C genotype 1 infection: the telaprevir early access program in patients from RomaniaSemantic proximity Read ↗

Advances in the management of hepatitis C.Semantic proximity Read ↗

Dermatological adverse effects during genotype-1 hepatitis C treatment with the protease inhibitors telaprevir and boceprevir. Patient management.Semantic proximity Read ↗

Management of untreated and nonresponder patients with chronic hepatitis C.Semantic proximity Read ↗

Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.Semantic proximity Read ↗

Management of the treatment-experienced patient infected with hepatitis C virus genotype 1: options and considerations.Semantic proximity Read ↗

Current therapy for hepatitis C.Semantic proximity Read ↗

Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.